Community-Based Primary Palliative Care Community of Practice Series 2

Palliative Care and Substance Use Disorders



Facilitator: Dr. Nadine Gebara

Presenter: Dr. Jenny Lau

Date: January 18, 2023

Territorial Honouring



The Palliative Care ECHO Project

The Palliative Care ECHO Project is a 5-year national initiative to cultivate communities of practice and establish continuous professional development among health care providers across Canada who care for patients with life-limiting illness and their families.

Stay connected: www.echopalliative.com

The Palliative Care ECHO Project is supported by a financial contribution from Health Canada. The views expressed herein do not necessarily represent the views of Health Canada.





LEAP Core

- Interprofessional course that focuses on the essential competencies to provide a palliative care approach.
- Taught by local experts who are experienced palliative care clinicians and educators.
- Delivered online or in-person.
- Ideal for any health care professional (e.g., physician, nurse, pharmacist, social worker, etc.) who provides care for patients with life-threatening and progressive life-limiting illnesses.
- Accredited by the CFPC and Royal College.



Learn more about the course and topics covered by visiting

www.pallium.ca/course/leap-core



Objectives of this Series

After participating in this series, participants will be able to:

- Augment their primary-level palliative care skills with additional knowledge and expertise related to providing a palliative care approach.
- Connect with and learn from colleagues on how they are providing a palliative care approach.



Overview of Sessions

Session#	SessionTitle	Date/ Time
Session 1	Pain: Beyond the Basics	Nov 9, 2022 from 1-2pm ET
Session 2	Communication: Part 1	Nov 23, 2022 from 1-2pm ET
Session 3	Communication: Part 2	Dec.7, 2022 from 1-2pm ET
Session 4	Palliative Care and Substance Use Disorders	Jan 18, 2023 from 1-2pm ET
Session 5	GI Symptoms in Palliative Care	Feb 1, 2023 from 1-2pm ET
Session 6	Delirium	Feb 15, 2023 from 1-2pm ET
Session7	Spiritual Care and Rituals around Death and Dying	Mar 1, 2023 from 1-2pm ET
Session 8	Palliative Sedation	Mar 15, 2023 from 1-2pm ET
Session 9	What's in store for Palliative Care in Canada: Policy, Advocacy and Implementation	Mar 29, 2023 from 1-2pm ET
Session 10	Grief and Bereavement: Beyond the Basics	Apr 12, 2023 from 1-2pm ET
Session 11	Practical Tips: Lessons from the Front Line	Apr 26, 2023 from 1-2pm ET



Welcome & Reminders

- Please introduce yourself in the chat! Let us know what province you are joining us from, your role and your work setting
- Your microphones are muted. There will be time during this session when you can unmute yourself for questions and discussion.
- You are welcome to use the chat function to ask questions and add comments throughout the session
- This session is being recorded and will be emailed to registrants within the next week.
- Remember not to disclose any Personal Health Information (PHI) during the session
- This 1-credit-per-hour Group Learning program has been certified by the College of Family Physicians of Canada for up to **11 Mainpro+** credits.



Disclosure

Relationship with Financial Sponsors:

Pallium Canada

- Not-for-profit
- Funded by Health Canada



Disclosure

This program has received financial support from:

- Health Canada in the form of a contribution program
- Generates funds to support operations and R&D from Pallium Pocketbook sales and course registration Fees

Facilitator/Presenter:

- Dr. Nadine Gebara: Nothing to disclose
- Dr. Jenny Lau: Research program is funded by Canadian Institutes of Health Research and Health Canada.



Disclosure

Mitigating Potential Biases:

• The scientific planning committee had complete independent control over the development of course content



Introductions

Facilitator:

Dr. Nadine Gebara, MD CCFP- PC Clinical co-lead of this ECHO series Palliative Care Physician at Toronto Western Hospital, University Health Network Family Physician at Gold Standard Health, Annex

Panelists:

Dr. Haley Draper, MD CCFP- PC Clinical co-lead of this ECHO series Palliative Care Physician at Toronto Western Hospital, University Health Network Family Physician at Gold Standard Health, Annex

Dr. Roger Ghoche, MDCM CCFP-PC, MTS Palliative Care and Rehabilitation Medicine, Mount Sinai Hospital- Montreal



Introductions

Panelists (continued):

Elisabeth Antifeau, RN, MScN, CHPCN(C), GNC(C) Regional Clinical Nurse Specialist (CNS-C), Palliative End of Life Care IH Regional Palliative End of Life Care Program Pallium Canada Master Facilitator & Coach, Scientific Consultant

Thandi Briggs, RSW MSW Care Coordinator, Integrated Palliative Care Program Home and Community Care Support Services Toronto Central

Claudia Brown, RN BSN Care Coordinator, Integrated Palliative Care Program Home and Community Care Support Services Toronto Central

Rev. Jennifer Holtslander, SCP-Associate, MRE, BTh Spiritual Care Provider

Support Team

Aliya Mamdeen Program Delivery Officer, Pallium Canada

Diana Vincze

Palliative Care ECHO Project Manager, Pallium Canada



Introductions

Presenter:

Dr. Jenny Lau

Dr. Jenny Lau MSc MD CCFP (PC) is the Medical Director of the Harold and Shirley Lederman Palliative Care Centre at Princess Margaret Cancer Center. She is a palliative care specialist who trained in family medicine at the University of Ottawa and then palliative medicine at the University of Alberta. She also has a Master of Science in Medical Science with Collaborative Specialization in Addiction Studies from the University of Toronto. Dr. Lau leads numerous local and national projects focused on addressing opioid use disorder and promoting safer opioid use in the context of life-threatening illnesses.



Palliative Care and Substance Use Disorders



Session Learning Objectives


Upon completing the session, participants will be able to:

- Describe approaches for providing pain and symptom management for people who non-medically use opioids
- Express the importance of harm reduction for people who use drugs



People who use drugs need palliative care

- Prevalence of drug use and substance use disorders are increasing around the world
- Ageing process among people with substance use problems is accelerated by 15 years
- Communicable disease outbreaks restrict access to healthcare services and magnify inequities experienced by people who use drugs





Access to Palliative Care

Policies to ensure access to palliative care

Policies to facilitate adherence with public health measures

Interventions to overcome structural barriers

Policies to increase access to controlled substances for palliative care

Structural vulnerability

Stigma

Criminalization of drug use

Organizational policies and resources

Country regulations around opioid and psychotropic substances







Strategies to overcome barriers

- Interdisciplinary collaboration to provide care for people who use drugs.
- Partnership with patients, caregivers, medical, community supports and home care teams.
- Reduce health disparities through strategies like service coordination and facilitating transitions in care.
- Integration of harm reduction measures into palliative care.



Prevalence of opioid use disorder (OUD)


1.6% to 4.6% for people over 11 years old

- Opioid use disorder is a complex, chronic biopsychosocial disorder where people engage in persistent opioid use despite harmful consequences
- 26.8 million people were living with OUD worldwide in 2016



DSM-V: OUD

- Tolerance*
- Withdrawal*
- More use than intended
- Craving for the substance
- Unsuccessful efforts to cut down
- Spends excessive time in acquisition
- Activities given up because of use
- Uses despite negative effects
- Failure to fulfill major role obligations
- Recurrent use in hazardous situations
- Continued use despite consistent social or interpersonal problems



*Not counted if opioid is prescribed by



Average age of death for people with OUD: 40 years

Average age of death for people on opioid agonist treatment: 49 years

Importance of identifying OUD

- High risk of comorbid medical and psychiatric conditions
- Restricted access to palliative care due to limited social supports, poverty and stigma
- Symptoms can be result of drug use and withdrawal
- Opioid use history is important
 - Avoid opioid of "choice"
 - May require higher opioid doses
 - Consider medication routes and formulations less likely to be diverted or used non-medically



Collaboration with opioid agonist treatment providers

Problematic opioid use ("aberrant behaviors")

- Observations or reports of prescription forgery*
- Reported theft or "borrowing" of opioids*
- Route alteration of prescribed opioids*
- $\circ~$ Reports of lost or stolen prescriptions
- Observable intoxication or withdrawal in clincal setting
- o Insistence on initation of opioids, higher doses and/or quantities of opioids
- Observed or reported opioid hoarding
- Self-titration of opioid doses without clinical approval
- Resisting changes to opioids despite adverse effects

*High priority as per Canadian Society of Palliative Care Physicians




Managing Concerning Behaviors in Patients Prescribed Opioids for Chronic Pain: A Delphi Study

Jessica S. Merlin, MD, MBA^{1,2}, Sarah R. Young, MD, MBA^{1,3}, Joanna L. Starrels, MD, MBA⁴, Soraya Azari, MD, MBA⁵, E. Jennifer Edelman, MD, MBA⁶, Jamie Pomeranz, MD, MBA⁷, Payel Roy, MD, MBA⁸, Shalini Saini, MD, MBA⁹, William C. Becker, MD, MBA^{6,10}, and Jane M. Liebschutz, MD, MBA⁸

Strategies are provided on how to manage the following concerning behaviors:

- Missing appointments
- Taking opioids for symptoms other than pain
- Using more opioid medications than prescribed
- Asking for an increase in opioid dose
- Aggressive behavior towards provider or staff
- Substance use



Across behaviors, patient education and information gathering are important approaches

Assessment of Risk of Problematic Opioid Use

- Post-traumatic stress*
- Sexual abuse history*
- o Personal or family history of alcohol use disorder
- \circ Current or history of tobacco use
- Current or history of non-medical drug use
- \circ $\,$ Current or history of injection drug use
- Criminal records related to substance use disorders
- $\circ~$ Past history of use of prescriptions not as prescribed
- \circ $\,$ Family history of problematic substance use
- \circ Age: 18 24 years, 65 years+
- History of depression, anxiety, personality disorders, somatization, chronic pain
- \circ Unstable housing
- \circ Financial instability

*High priority as per Canadian Society of Palliative Care Physicians



Assessment of Risk of Opioid Overdose

- Receiving opioid prescriptions from two or more physicians*
- Benzodiazepene use
- o Alcohol use
- \circ $\,$ History of previous opioid overdose $\,$
- $\circ~$ Active or past history of substance use disorder
- Urine drug tests
- Older age (65+ years)
- Renal or liver impairment
- Muscle relaxant use
- \circ Sleep medication or hypnotic use
- Methadone use for pain or opioid use disorder management
- Opioid naïve patients
- Untreated psychiatric conditions
- Obstructive sleep apnea

*High priority as per Canadian Society of Palliative Care Physicians





2021, Vol. 35(7) 1295-1322

Palliative Medicine

(S)SAGE

© The Author(s) 2021

Article reuse guidelines:

sagepub.com/journals-permissions

DOI: 10.1177/02692163211015567 journals.sagepub.com/home/pmj

Assessment tools for problematic opioid use in palliative care: A scoping review

Jenny Lau^{1,2,3}, Paolo Mazzotta^{2,4}, Rouhi Fazelzad⁵, Suzanne Ryan^{3,6}, Alissa Tedesco⁴, Andrew J. Smith⁷, Abhimanyu Sud^{2,8}, Andrea D. Furlan^{9,10,11} and Camilla Zimmermann^{3,6,12} Identified 32 studies that used questionnaires: CAGE, CAGE-AID, ORT, SOAPP, SOAPP-R, SOAPP-SF None of the studies developed or validated the questionnaires for patients receiving palliative care²⁷



Opioid Prescribing Practices

The following **opioid prescribing practices** for patients receiving care in **outpatient palliative care clinics or home palliative care visits** are strongly recommended:

- Physicians should have access to regional prescription monitoring programs to track previously dispensed prescriptions
- If the primary prescriber of opioids is absent, detailed pain management plans and documentation should be provided to the covering clinician
- Patients who have opioid use disorder or are at high-risk of problematic opioid use and overdose should receive daily to weekly dispensing of opioids
- Clinicians should provide a max of one month supply of opioids with each prescription
- Each patient should have only one prescriber

*High priority as per Canadian Society of Palliative Care Physicians




Structured Opioid Therapy

• Continued opioid prescribing under conditions that limit aberrant drug related behaviours.

- Treatment agreement
- **Dispense small amounts** frequently (e.g., 1–2 times per week)
- Monitor closely with urine drug tests, pill counts, office visits
- Switch to buprenorphine or methadone treatment if structured opioid therapy fails (e.g., patient continues to access opioids from other sources)



Collaborative care



Patients with symptom management concerns and active problematic opioid use, opioid use disorder and/or history of overdose should be jointly managed with an addictions medicine specialist.

ncc: mtps://www.piquenewsmagazine.com/bc-news/grant-funding-awarded-to-help-addiction-support-services-3303901

Managing pain for patients with OUD

- Buprenorphine
- Methadone
- Structured opioid therapy
- Non-opioid adjuvants
- Interventional modalities
- Non-pharmacologic modalities



Buprenorphine: Pain Management

ADVANTAGES:

- Ceiling effect for respiratory depression
- Less development of tolerance
- Antihyperalgesic effect
- Less effect on hypogonadism
- Less immunosuppression compared with morphine and fentanyl
- Ease of use un elderly and in renal impairment
- Possible efficacy in neuropathic pain



Buprenorphine: Dosing

- Buprenorphine-naloxone
- Naloxone has no major clinical effect when administered sublingually.
- Dose to effect
- Analgesic efficacy: 6-8 hrs
- For acute-on-chronic pain (eg surgery), consider gently tapering dose as much as possible without destabilizing patient. DO NOT DISCONTINUE.



Methadone: Pain Management

- Methadone maintenance therapy only prevents withdrawals and cravings
- If patients are experience acute pain...

Mild – moderate pain: Non-opioid medications

Moderate – severe pain: Appropriately prescribed opioids similar for people with similar pain

• There is limited evidence but **dividing methadone** into every 4 to 8 hour doses or by **continuous infusion** may be useful for analgesia.





Consensus Statement | Substance Use and Addiction Expert Panel Consensus on Management of Advanced Cancer–Related Pain in Individuals With Opioid Use Disorder

Jessica S. Merlin, MD, PhD; Dmitry Khodyakov, PhD; Robert Arnold, MD; Hailey W. Bulls, PhD; Emily Dao, MS; Jennifer Kapo, MD, MSCE; Caroline King, PhD; Diane Meier, MD; Judith Paice, PhD, RN; Christine Ritchie, MD, MSPH; Jane M. Liebschutz, MD, MPH

Patient with advanced cancer and OUD taking buprenorphine-naloxone...

- Regardless of prognosis, appropriate to continue buprenorphine-naloxone with TID dosing
- Discontinue buprenorphine-naloxone and start methadone with TID dosing
- For patients with prognosis of weeks to months: continue buprenorphine-naloxone and add full agonist opioid, Note: "uncertain appropriateness" to discontinue buprenorphine-naloxone and start full agonist opioid other than methadone
- For patients with prognosis of months to years: "uncertain appropriateness" to add full agonist opioid

Patient with advanced cancer and OUD taking methadone...

- Regardless of prognosis, appropriate to take over prescribing and dose BID or TID
- For patients with prognosis of weeks to months: continue methadone and add full agonist opioid
- For patients with prognosis of months to years: "uncertain appropriateness" to add full agonist opioid



Harm reduction

Canadian Mental Health Association defines harm reduction as "evidence based, clientcentred approach that seeks to reduce the health and social harms associated with addiction and substance use, without necessarily requiring people who use substances from abstaining or stopping."

- Provides people who use drugs a choice of how they will minimize harms through non-judgemental and non-coercive strategies
- Examples:
 - Nicotine patch for smoking cessation
 - Needle exchange programs for people who inject drugs
 - Supervised injection sites
 - Safer supply (i.e. provision of prescription medications as a safer alternative to toxic illegal drug supply)



Patient Education


All **patients** receiving palliative care and opioid prescriptions and their **caregivers** should be educated on the following topics:

- \circ $\,$ Indications for opioid use
- Opioid adverse effects
- Difference between physical dependence and opioid use disorders
- Chemical coping with opioids
- \odot Opioid overdose signs and symptoms
- Opioid withdrawal symptoms
- Driving or operating machinery
- Safe storage of opioids*
- Safe disposal of opioids*

*High priority as per Canadian Society of Palliative Care Physicians















Case-Based Discussion

CASE

Ms. B is a 50-year-old woman who was recently diagnosed with metastatic breast cancer after she was admitted to hospital from acetaminophen toxicity. During the hospital admission, she informed the inpatient palliative care consultation team that she was using large quantities of Tylenol #1 and illegal fentanyl to manage her severe chest wall pain. She also stated that she was regularly using crack but did not believe it was problematic. She was offered to be referred to the addictions medicine team but declined the offer. She was discharged home with outpatient appointments with oncology and palliative care.

Social situation:

- Lives alone in a supportive housing complex
- 12 year old son is living with aunt because he was removed from his mom's home by child protection services
- 25 year old daughter lives in BC
- Main supports are two sisters who live outside of the city
- Unemployed, financial assistance programs

If you were her primary care or outpatient palliative care provider:

- What are the challenges you anticipate that you would face with providing palliative care?
- How would you manage her pain?
- What other teams or individuals would you want to involve in her care?



Session Wrap Up

- Please fill out our feedback survey, a link has been added into the chat.
- A recording of this session will be emailed to registrants within the next week.
- We hope to see you again at our next session taking place on Feb 1, 2023 from 1-2pm ET on the topic of GI Symptoms in Palliative Care.
- Thank you for your participation during our second series!



Thank You



Stay Connected www.echopalliative.com

Urine Drug Screens (UDS)

- Reduces illicit drug use in chronic pain patients receiving opioids
- Illicit drug use reduced by 50% in a group with urine testing compared to previous data


Manchikanti L et al.. Pain Physician. 2006 Jan;9(1):57-60.



UDT: Immunoassay - "Screening Test"

- Uses antibodies to detect specific substance or class
- VERY SENSITIVE: Detection time 3-5 days
- LOW SENSITIVITY for SEMI-SYNTHETIC OPIOIDS
- NOT SENSITIVE for SYNTHETIC OPIOIDS (unless specified)
- Cheap, Rapid, Point-Of-Care
- NEED TO CONFIRM ABNORMALS








UDT: Gas Chromatography/Mass Spectroscopy (GCMS) "Confirmatory Test"

- Sensitivity depends on cut-off criteria
- MUCH MORE SPECIFIC
 - Occasional False + for Amphetamines
- Often used as confirmatory testing
- Distinguishes molecules among a class
- Can detect semi- and synthetic opioids
- Expensive
- Must be sent to lab
- Detection Time 1-2 days






47

Simplified Schematic of Metabolic Pathways for Opioids





* Not specifically detected by the assay



Drug	Number of days drug is detectable	
	Immunoassay	Chromatography
Benzodiazepines (regular use)	20+ days for regular diazepam use Immunoassay does not distinguish different benzodiazepines Intermediate-acting benzodiazepines such as clonazepam often undetected at therapeutic doses	Can distinguish specific benzodiazepines
Cannabis	20+	Not used for cannabis
Cocaine + metabolite	3-7	1-2
Codeine	2-5	1-2 (codeine metabolized to morphine and also hydrocodone when used at high doses)
Hydrocodone	2-5	1-2
Hydromorphone	2-5	1-2
Meperidine	1 (often missed)	1
Morphine	2-5	1-2: Morphine can be metabolized to hydromorphone at high doses
Oxycodone	Often missed unless a specific test strip is used	1-2

Source: Adapted from Brands, 1998.



This table is adapted with permission from the Canadian Guideline for Safe and Effective Use of Opioids for Chronic Non-Cancer Pain © 2010 National Opioid Use Guideline Group (NOUGG). Source: CAMH https://www.porticonetwork.ca/web/opioidtoolkit/assessment/urine-drug-testing I understand that I am receiving opioid medication from Dr. ______to treat my pain condition. I agree to the following:

1. I will not seek opioid medications from another physician. Only Dr. ______ will prescribe opioids for me.

2. I will not take opioid medications in larger amounts or more frequently than is prescribed by Dr.

- 3. I will not give or sell my medication to anyone else, including family members; nor will I accept any opioid medication from anyone else.
- 4. I will not use over-the-counter opioid medications such as 222's and Tylenol® No. 1.
- 5. I understand that if my prescription runs out early for any reason (for example, if I lose the medication, or take more than prescribed), Dr. ______ will not prescribe extra medications for me; I will have to wait until the next prescription is due.
- 6. I will fill my prescriptions at one pharmacy of my choice; pharmacy name:

7. I will store my medication in a secured location.

l understand that if l break these conditions, Dr. _____ may choose to cease writing opioid prescriptions for me.



Source:

Canadian Guideline for Safe and Effective Use of Opioids for Chronic Non-Cancer Pain Appendix B-5

http://nationalpaincentre.mcmaster. ca/opioid/cgop_b_app_b05.html

50